Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Addex Receives Nasdaq Notification Regarding Minimum Bid
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Addex
Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s
Cohort 1 progressing through Part 2Cohort 2 recruiting patients…
Addex Convenes Annual General Meeting 2023
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland,…
Addex Completes $5.0 Million Equity Financing
Proceeds to advance allosteric modulator therapeutic pipeline…
- Advertisement -
Addex Therapeutics to Release Full-Year 2022 Financial
Geneva, Switzerland, March 28, 2023 – Addex Therapeutics (SIX and…
Addex Strategic Partner Completes Enrollment in ADX71149
<!-- Name:DistributionId Value:1000780716 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Addex Provides Corporate Update and Financial Guidance
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and…
Addex Reports Q3 2022 Financial Results and Provides
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November…